Harbour BioMed Taps Metabolic Disease Veteran Dr. Bob Zhang as Franchise President
Event summary
- Harbour BioMed appointed Dr. Bob Zhang as President of its Metabolic Disease Franchise on August 6, 2026.
- Zhang will lead strategy and operations for therapies targeting obesity, MASH/liver diseases, and cardiovascular disorders.
- The move underscores Harbour BioMed's push into metabolic diseases, a fast-growing area of unmet medical need.
- Zhang brings 20+ years of experience in metabolic and liver disease R&D from roles at Epigenic Therapeutics, Kunming Biomed, and Sanofi.
The big picture
Harbour BioMed's appointment of Zhang signals a deeper commitment to metabolic diseases amid growing global demand for innovative therapies. The move comes as cardiovascular diseases remain the leading cause of mortality worldwide, with significant unmet needs in areas where metabolic dysfunction is a key driver. By leveraging its proprietary antibody discovery technologies and expanding expertise in metabolic biology, Harbour BioMed aims to develop next-generation biologics that address complex disease mechanisms.
What we're watching
- Pipeline Acceleration
- How quickly Zhang can advance Harbour BioMed's differentiated pipeline of metabolic disease therapies.
- Strategic Partnerships
- Whether Zhang's industry connections will drive new collaborations to bolster the franchise.
- Execution Risk
- The pace at which Harbour BioMed can translate its antibody technologies into impactful metabolic disease treatments.